次世代定序(NGS) 服務市場規模、佔有率和成長分析：按服務類型、工作流程、應用、最終用戶和地區分類－2026-2033 年產業預測

2024 年全球次世代定序(NGS) 服務市場價值為 125 億美元，預計到 2025 年將成長至 141.5 億美元，到 2033 年將成長至 381.5 億美元，在預測期（2026-2033 年）內複合年成長率為 13.2%。

全球次世代定序(NGS) 服務市場涵蓋實驗室定序和生物資訊學，用於產生和分析高通量 DNA 和 RNA 數據，這些數據對於精準醫療、病原體定序和農業創新等研究和臨床應用至關重要。技術進步顯著降低了定序成本並提高了通量，擴大了定序服務的可近性，並推動了臨床對認證工作流程的需求。醫院、生物製藥公司和公共衛生機構正在尋求經臨床檢驗的檢測方法，而專業服務提供者則在品管系統和生物資訊學方面進行投資，以滿足認證標準。癌症伴隨診斷、非侵入性產前檢測和病原體監測正在推動市場成長，人工智慧在透過增強數據處理和變異檢測來提高準確性方面發揮關鍵作用。這些進步正在簡化工作流程，提高可靠性，並在快速成長的 NGS 市場中開闢新的商機。

全球次世代定序(NGS) 服務市場的成長要素

全球次世代定序(NGS) 服務市場的主要驅動力是日益成長的個人化醫療需求。基因組學的進步以及對疾病遺傳基礎的深入了解，提高了基於個別患者基因譜最佳化治療方案的能力。隨著醫療專業人員和研究人員認知到 NGS 在識別突變、指南藥物選擇和預測治療反應方面的潛力，旨在將基因組數據整合到臨床實踐中的投資和研究舉措正在激增。這種向精準醫療的轉變不僅改善了患者的治療效果，也推動了 NGS 服務在全球的擴張。

全球次世代定序(NGS) 服務市場的限制因素

全球次世代定序(NGS) 服務市場的主要限制因素是先進定序技術和必要基礎設施的高成本。 NGS 的複雜性和所需的專業技術可能會阻礙小規模實驗室和機構採用這些服務，從而限制市場成長。此外，對資料隱私和基因資訊相關倫理問題的擔憂也會阻礙 NGS 的廣泛接受和應用。基因組數據使用方面的監管挑戰以及區域法規結構的差異進一步加劇了這種情況，為市場准入和擴張設置了更多障礙。

次世代定序（NGS）服務市場的全球趨勢

全球次世代定序(NGS) 服務市場正呈現出顯著的臨床整合趨勢，而定序服務正從研究性應用轉向常規診斷流程中不可或缺的一部分。這一轉變的特點是需要更有效率的檢體到結果處理流程以及與醫療服務提供者更緊密的合作。提供標準化檢測、臨床級報告以及與電子健康記錄無縫互通性的服務合作夥伴正日益受到青睞。因此，對經過檢驗的流程、獲得認證的檢查室和諮詢支援的需求也日益成長，這些服務能夠將基因組分析結果轉化為可執行的醫療決策，並使 NGS 服務在推進個人化醫療方面發揮關鍵作用。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球次世代定序(NGS) 服務市場規模：依服務類型分類

• 全基因組定序 (WGS) 服務
• 全外EXOME定序 (WES) 服務
• 標靶定序服務
• RNA測序（RNA-Seq）服務
• 單細胞定序服務
• 表觀基因定序服務
• 元基因組定序服務
• 從頭定序服務
• 其他

全球次世代定序(NGS) 服務市場規模：依工作流程分類

• 樣品製備服務
• 定序服務
• 數據分析與生物資訊服務
• 資料儲存和管理服務

全球次世代定序(NGS) 服務市場規模：按應用領域分類

• 腫瘤學
• 生殖健康和產前檢查
• 臨床診斷
• 感染疾病調查
• 遺傳疾病和罕見疾病的研究
• 藥物發現與開發
• 農業和畜牧業調查
• 微生物組分析
• 法醫學
• 其他

全球次世代定序(NGS) 服務市場規模：依最終用戶分類

• 製藥和生物技術公司
• 學術研究機構
• 醫院/診斷檢查室
• 受託研究機構（CRO）
• 政府和公共衛生機構
• 其他

全球次世代定序(NGS) 服務市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Illumina
• Thermo Fisher Scientific
• QIAGEN
• Eurofins Scientific
• BGI Genomics
• Macrogen
• Azenta Life Sciences
• Novogene
• F. Hoffmann-La Roche
• Pacific Biosciences
• Oxford Nanopore Technologies
• GENEWIZ
• Personalis
• Veracyte
• Quest Diagnostics
• Laboratory Corporation of America Holdings
• SOPHiA GENETICS
• 10x Genomics
• Adaptive Biotechnologies
• Natera

結論與建議

Global Next-Generation Sequencing (Ngs) Services Market size was valued at USD 12.5 Billion in 2024 and is poised to grow from USD 14.15 Billion in 2025 to USD 38.15 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).

The global next-generation sequencing (NGS) services market includes laboratory sequencing and bioinformatics to generate and interpret high-throughput DNA and RNA data, crucial for research and clinical applications like precision medicine, pathogen surveillance, and agricultural innovation. Advancements have drastically reduced sequencing costs and increased throughput, broadening access and fostering clinical demand for accredited workflows. As hospitals, biopharma, and public health agencies seek clinically validated assays, specialized providers invest in quality systems and bioinformatics to meet accreditation standards. Growth drivers include oncology companion diagnostics, noninvasive prenatal testing, and pathogen surveillance, with AI playing a pivotal role in enhancing accuracy through improved data processing and variant calling. This evolution streamlines workflows, bolsters reliability, and opens new revenue opportunities in the rapidly expanding NGS landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next-Generation Sequencing (Ngs) Services market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next-Generation Sequencing (Ngs) Services Market Segments Analysis

Global next-generation sequencing (ngs) services market is segmented by service type, workflow, application, end user and region. Based on service type, the market is segmented into Whole Genome Sequencing (WGS) Services, Whole Exome Sequencing (WES) Services, Targeted Sequencing Services, RNA Sequencing (RNA-Seq) Services, Single-Cell Sequencing Services, Epigenomics Sequencing Services, Metagenomics Sequencing Services, De Novo Sequencing Services and Others. Based on workflow, the market is segmented into Sample Preparation Services, Sequencing Services, Data Analysis & Bioinformatics Services and Data Storage & Management Services. Based on application, the market is segmented into Oncology, Reproductive Health & Prenatal Testing, Clinical Diagnostics, Infectious Disease Research, Genetic & Rare Disease Research, Drug Discovery & Development, Agricultural & Animal Research, Microbiome Analysis, Forensics and Others. Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Laboratories, Contract Research Organizations (CROs), Government & Public Health Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next-Generation Sequencing (Ngs) Services Market

A key market driver for the global next-generation sequencing (NGS) services market is the increasing demand for personalized medicine. Advancements in genomics and a growing understanding of the genetic basis of diseases have led to enhanced capabilities in tailoring treatments to individual patients based on their genetic profiles. As healthcare providers and researchers recognize the potential of NGS in identifying mutations, guiding drug selection, and predicting treatment responses, there is a surge in investments and research initiatives aimed at integrating genomic data into clinical practices. This shift towards precision medicine not only improves patient outcomes but also fuels the expansion of NGS services worldwide.

Restraints in the Global Next-Generation Sequencing (Ngs) Services Market

A significant market restraint for the global next-generation sequencing (NGS) services market is the high costs associated with advanced sequencing technologies and the necessary infrastructure. The complexity and technical expertise required for NGS can deter smaller laboratories and institutions from adopting these services, limiting market growth. Additionally, concerns regarding data privacy and the ethical implications of genetic information can hinder widespread acceptance and utilization. Regulatory challenges surrounding the use of genomic data and variations in regulatory frameworks across regions further complicate the landscape, creating additional barriers for market entry and expansion.

Market Trends of the Global Next-Generation Sequencing (Ngs) Services Market

The Global Next-Generation Sequencing (NGS) Services market is witnessing a significant trend toward enhanced clinical integration, with sequencing services transitioning from research applications to becoming an essential component of routine diagnostic workflows. This shift is characterized by the demand for streamlined sample-to-result processes and stronger collaborations with healthcare providers. Service partners that offer standardized assays, clinical-grade reporting, and seamless interoperability with electronic health records are increasingly favored. Consequently, there is a rising need for validated pipelines, certified laboratories, and consultative support, thereby transforming genomic insights into actionable care decisions and solidifying NGS services as vital players in the advancement of personalized medicine.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Next-Generation Sequencing (NGS) Services Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Whole Genome Sequencing (WGS) Services
• Whole Exome Sequencing (WES) Services
• Targeted Sequencing Services
• RNA Sequencing (RNA-Seq) Services
• Single-Cell Sequencing Services
• Epigenomics Sequencing Services
• Metagenomics Sequencing Services
• De Novo Sequencing Services
• Others

Global Next-Generation Sequencing (NGS) Services Market Size by Workflow & CAGR (2026-2033)

• Market Overview
• Sample Preparation Services
• Sequencing Services
• Data Analysis & Bioinformatics Services
• Data Storage & Management Services

Global Next-Generation Sequencing (NGS) Services Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Reproductive Health & Prenatal Testing
• Clinical Diagnostics
• Infectious Disease Research
• Genetic & Rare Disease Research
• Drug Discovery & Development
• Agricultural & Animal Research
• Microbiome Analysis
• Forensics
• Others

Global Next-Generation Sequencing (NGS) Services Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Diagnostic Laboratories
• Contract Research Organizations (CROs)
• Government & Public Health Organizations
• Others

Global Next-Generation Sequencing (NGS) Services Market Size & CAGR (2026-2033)

• North America (Service Type, Workflow, Application, End User)
  • US
  • Canada
• Europe (Service Type, Workflow, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Workflow, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Workflow, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Workflow, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Azenta Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novogene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GENEWIZ
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOPHiA GENETICS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 10x Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations